Xeljanz Insurance Denial Appeal Guide

Why Xeljanz Gets Denied

Since the FDA added boxed warnings about cardiovascular and cancer risks, some insurers have moved Xeljanz to higher restriction tiers or removed it from formularies entirely. Step therapy through TNF inhibitors is almost always required.

Common Denial Reasons

• Step therapy failure documentation insufficient
• Safety concerns cited (FDA boxed warning)
• Non-formulary medication
• Prior authorization expired or not submitted
• Age restrictions (some plans restrict for patients over 65)

Appeal Strategy

1. Address safety concerns directly — your doctor should explain why benefits outweigh risks for your specific case
2. Document TNF inhibitor failures — detailed records of each failed biologic
3. Cite ACR treatment guidelines — JAK inhibitors are guideline-recommended after DMARD failure
4. Include disease activity scores — DAS28, CDAI, or HAQ showing moderate-to-severe disease
5. Request exception if non-formulary — medical exception requests bypass formulary restrictions

Tips for Success

The strongest appeals include a detailed physician letter addressing the specific FDA safety concerns for YOUR patient profile. If you are under 50 with no cardiovascular risk factors, emphasize this clearly.